Table 3.
Short-term net costs of the vaccination programme, long-term productivity benefits of vaccination, and ICERs
| Short-term net costs of vaccination with LSD and MSD burden | Long-term average retirement income effect scenario with LSD and MSD burden | Total net costs with LSD and MSD burden, average retirement income effect scenario | Short-term net costs of vaccination with MSD only burden | Long-term early retirement income effect scenario with MSD only burden | Total net costs with MSD only burden, early retirement income effect scenario | Short-term ICERs of vaccination with LSD and MSD burden | Total ICERs of vaccination with LSD and MSD burden | Short-term ICERs of vaccination with MSD only burden | Total ICERs of vaccination with MSD only burden | |
|---|---|---|---|---|---|---|---|---|---|---|
| LICs and LMICs only | ||||||||||
| African region | $2 128 410 503 | $18 190 037 895 | −$16 061 627 393 | $3 168 081 088 | $4 448 008 377 | −$1 279 927 289 | $148 | Cost-saving | $253 | Cost-saving |
| Region of the Americas | $116 458 342 | $387 380 874 | −$270 922 531 | $139 774 342 | $118 090 266 | $21 684 076 | $1468 | Cost-saving | $2076 | $1 |
| Eastern Mediterranean region | $1 444 441 843 | $4 199 309 262 | −$2 754 867 419 | $1 705 034 748 | $1 170 111 530 | $534 923 218 | $962 | Cost-saving | $1366 | $37 |
| European region | $169 596 359 | $689 762 644 | −$520 166 285 | $188 993 601 | $194 381 649 | −$5 388 048 | $6258 | Cost-saving | $8568 | Cost-saving |
| South-East Asia Region | $2 558 955 923 | $55 541 011 504 | −$52 982 055 580 | $2 854 852 733 | $11 883 800 004 | −$9 028 947 271 | $3679 | Cost-saving | $5207 | Cost-saving |
| Western Pacific region | $876 685 851 | $5 763 024 543 | −$4 886 338 692 | $918 655 357 | $1 354 206 683 | −$435 551 327 | $7167 | Cost-saving | $9085 | Cost-saving |
| Gavi-eligible countries | $5 175 827 295 | $74 975 327 035 | −$69 799 499 741 | $6 586 343 447 | $16 654 760 176 | −$10 068 416 730 | $308 | Cost-saving | $458 | Cost-saving |
| Global | $7 294 548 821 | $84 770 526 722 | −$77 475 977 900 | $8 975 391 870 | $19 168 598 510 | −$10 193 206 640 | $414 | Cost-saving | $596 | Cost-saving |
| LICs, LMICs, and UMICs | ||||||||||
| African region | $2 342 074 114 | $19 054 584 092 | −$16 712 509 979 | $3 498 838 733 | $4 725 160 835 | −$1 226 322 102 | $161 | Cost-saving | $276 | Cost-saving |
| Region of the Americas | $1 172 321 009 | $12 749 072 001 | −$11 576 750 992 | $1 593 900 789 | $4 004 414 220 | −$2 410 513 431 | $4237 | Cost-saving | $6913 | Cost-saving |
| Eastern Mediterranean region | $1 844 211 327 | $4 977 018 137 | −$3 132 806 809 | $2 133 757 615 | $1 404 033 854 | $729 723 761 | $1210 | Cost-saving | $1687 | $50 |
| European region | $711 481 873 | $3 317 730 095 | −$2 606 248 221 | $794 126 013 | $975 865 603 | −$181 739 590 | $14 840 | Cost-saving | $20 507 | Cost-saving |
| South-East Asia region | $4 073 465 298 | $62 269 412 660 | −$58 195 947 362 | $4 439 808 108 | $13 710 812 232 | −$9 271 004 123 | $4893 | Cost-saving | $6701 | Cost-saving |
| Western Pacific region | $5 507 077 021 | $31 336 480 661 | −$25 829 403 640 | $5 858 927 274 | $7 837 815 440 | −$1 978 888 166 | $22 990 | Cost-saving | $30 111 | Cost-saving |
| Gavi-eligible countries | $5 175 827 295 | $74 975 327 035 | −$69 799 499 741 | $6 586 343 447 | $16 654 760 176 | −$10 068 416 730 | $308 | Cost-saving | $458 | Cost-saving |
| Global | $15 650 630 642 | $133 704 297 646 | −$118 053 667 004 | $18 319 358 533 | $32 658 102 184 | −$14 338 743 651 | $849 | Cost-saving | $1170 | Cost-saving |
Average retirement age was defined as 64 years as per the OECD, whereas early retirement age was defined as 50 years. ICERs are presented from the companion cost-effectiveness analysis along with new ICERs calculated by combining short-term and long-term benefits; they are shown as 2019 US$ per DALYs averted. Cost-saving indicates that net costs are negative, indicating the costs of vaccination are fully offset by the benefits of vaccination. DALY=disability-adjusted life year. ICER=incremental cost-effectiveness ratio. LSD=less-severe disease. MSD=moderate-to-severe disease. OECD=Organisation for Economic Development and Co-operation.